Gapping up
In reaction to strong earnings/guidance: DDD +11.4%, SUNW +10.7%, VICL+7.4%, HNRG +7.2%, KNDI +7%, RDNT +5.8%, CAS +4.4%, ATNM +2.6%, EARS+2.2%, ICON +0.8%, VCEL +0.5%
M&A news: TFM +23.6% (confirms it will be acquired by Apollo Global Management (APO) for $28.50/share in cash, or ~$1.36 bln; go-shop period included in deal), HOT +8.5% (receives a non-binding proposal from a consortium of companies for $76.00/share in cash), IHG +3.8% (HOT peer)
Other news: GWPH +117.1% (announces positive phase 3 study results for epidiolex; achieves primary endpoint of a significant reduction in convulsive seizures vs placebo), ZYNE +54% (in symp with GWPH, also reported earnings), CLBS +20.5% (Caladrius Biosciences subsidiary, PCT, enters into a global collaboration with Hitachi Chemical (HCHMY) that includes licensing, development and equity components), THLD +8.2% (cont strength), GBSN+2.9% (cont vol pre-mkt), SUNE +2.6% (cont strength), AINV +2.2% (to reduce fees for FY 17 to 1.5% on gross assets and Apollo Global Management (APO) informs it will purchase $50 mln of AINV common stock), CLI +0.9% (files ~1.148 mln share common stock offering by selling stockholders )
Analyst comments: TSLA +1.7% (upgraded to Outperform from Neutral at Robert W. Baird), HCA +1.2% (upgraded to Overweight from Neutral at JP Morgan)
In reaction to strong earnings/guidance: DDD +11.4%, SUNW +10.7%, VICL+7.4%, HNRG +7.2%, KNDI +7%, RDNT +5.8%, CAS +4.4%, ATNM +2.6%, EARS+2.2%, ICON +0.8%, VCEL +0.5%
M&A news: TFM +23.6% (confirms it will be acquired by Apollo Global Management (APO) for $28.50/share in cash, or ~$1.36 bln; go-shop period included in deal), HOT +8.5% (receives a non-binding proposal from a consortium of companies for $76.00/share in cash), IHG +3.8% (HOT peer)
Other news: GWPH +117.1% (announces positive phase 3 study results for epidiolex; achieves primary endpoint of a significant reduction in convulsive seizures vs placebo), ZYNE +54% (in symp with GWPH, also reported earnings), CLBS +20.5% (Caladrius Biosciences subsidiary, PCT, enters into a global collaboration with Hitachi Chemical (HCHMY) that includes licensing, development and equity components), THLD +8.2% (cont strength), GBSN+2.9% (cont vol pre-mkt), SUNE +2.6% (cont strength), AINV +2.2% (to reduce fees for FY 17 to 1.5% on gross assets and Apollo Global Management (APO) informs it will purchase $50 mln of AINV common stock), CLI +0.9% (files ~1.148 mln share common stock offering by selling stockholders )
Analyst comments: TSLA +1.7% (upgraded to Outperform from Neutral at Robert W. Baird), HCA +1.2% (upgraded to Overweight from Neutral at JP Morgan)